1. Japan Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Torii Pharmaceutical Co., Ltd.

Torii Pharmaceutical Co., Ltd.

TRXPF
Torii Pharmaceutical Co., Ltd.US flagOther OTC
24.57
USD
- -
- -
690.70MMarket Cap
2013 Y
2014 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
TTM
Revenue per Share
3,735,142,857.14
4,150,571,428.57
3,107,285,714.29
4,455,500,000
4,300,428,571.43
4,581,000,000
4,467,857,142.86
3,071,214,285.71
2,978,500,000
3,356,214,285.71
3,492,428,571.43
3,902,642,857.14
4,316,071,428.57
4,089,071,428.57
Basic EPS, GAAP
132,071,428.57
239,428,571.43
172,785,714.29
251,928,571.43
202,785,714.29
337,000,000
83,142,857.14
1,954,785,714.29
249,642,857.14
241,000,000
281,714,285.71
294,214,285.71
360,142,857.14
375,285,714.29
Free Cash Flow per Basic Share
-85,642,857.14
-72,285,714.29
-106,642,857.14
246,857,142.86
188,714,285.71
397,142,857.14
541,714,285.71
2,996,642,857.14
-275,285,714.29
-37,857,142.86
152,785,714.29
-238,500,000
247,071,428.57
- -
Dividend per Share
80,857,142.86
80,857,142.86
80,857,142.86
88,928,571.43
97,000,000
96,142,857.14
96,142,857.14
96,214,285.71
96,214,285.71
96,285,714.29
96,285,714.29
252,857,142.86
261,000,000
- -
Book Value per Share
1,046,500,000
1,205,214,285.71
1,297,214,285.71
1,460,285,714.29
1,566,071,428.57
1,806,928,571.43
1,794,000,000
3,652,571,428.57
3,805,928,571.43
3,950,642,857.14
4,136,071,428.57
4,177,428,571.43
4,276,642,857.14
8,204,928,571.43
Tangible Book Value per Share
5,432,857,142.86
5,599,571,428.57
5,671,785,714.29
5,847,857,142.86
5,904,214,285.71
6,164,285,714.29
6,173,071,428.57
8,042,785,714.29
8,189,071,428.57
8,321,571,428.57
8,479,071,428.57
8,550,214,285.71
8,657,928,571.43
8,576,214,285.71
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
52,292
58,108
43,502
62,377
60,206
64,134
62,550
42,997
41,699
46,987
48,894
54,637
60,425
57,247
Operating Margin (%)
5.35
8.59
9.28
7.89
6.35
9.8
7.92
3.34
11.37
9.92
11.34
9.23
11.26
11.65
Depreciation Expense
1,061
1,089
924
1,457
1,339
1,174
1,040
985
582
413
454
459
408
- -
Net Income, GAAP
1,849
3,352
2,419
3,527
2,839
4,718
1,164
27,367
3,495
3,374
3,944
4,119
5,042
5,254
Effective Tax Rate (%)
36.84
34.7
36
32.9
29.98
25.97
61.55
27.41
17.25
29.2
31.07
26.34
25.01
25.25
Profit Margin (%)
3.54
5.77
5.56
5.65
4.72
7.36
1.86
63.65
8.38
7.18
8.07
7.54
8.34
9.18
Working Capital
57,523
59,129
60,730
62,683
66,813
68,112
64,179
85,075
87,281
84,920
78,382
75,644
76,487
73,958
LT Debt
71
193
387
725
571
465
380
294
209
275
241
22
281
- -
Total Equity
76,699
79,016
80,223
82,825
83,555
87,117
87,092
113,125
115,089
117,014
119,224
120,132
121,532
120,442
Return on Invested Capital (%)
2.27
4.12
3.19
3.95
3.13
5.34
2.15
0.98
3.29
2.81
3.19
3.06
4.17
4.15
Return on Capital (%)
12.83
20.87
13.38
17.46
12.84
19.44
4.53
70.99
6.65
6.17
6.91
7.03
8.47
4.61
Return on Common Equity (%)
12.94
21.27
13.81
18.27
13.4
19.98
4.62
71.78
6.69
6.21
6.97
7.08
8.52
4.61

Capital Structure

FRC

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
ST Debt
222
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
22
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
- -
- -
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
Total Current Assets
88,148
85,620
87,165
Cash, Cash Equivalents & STI
44,003
40,678
42,174
Accounts Receivable, Net
28,502
27,870
27,883
Inventories
10,742
12,077
11,902
Total Current Liabilities
12,504
13,181
13,207
Payables & Accruals
- -
- -
- -
ST Debt
222
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.55%
1.45%
1.17%
Free Cash Flow
-91.37%
-231.74%
-203.59%
Net Income, GAAP
222.13%
-9.39%
22.41%
Sales/Revenue/Turnover
4.88%
7.21%
10.59%
Total Cash Common Dividend
- -
- -
3.22%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
11,811
13,888
13,433
15,505
54,637
2024
13,451
14,858
- -
- -
60,425
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
-20,571,428.57
- -
- -
- -
294,214,285.71
2024
62,714,285.71
- -
- -
- -
360,142,857.14
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
252,857,142.86
2024
- -
- -
- -
- -
261,000,000
2025
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Goichi Matsuda
Full Time Employees
583
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Address
Torii Nihonbashi Bldg. Tokyo Japan 103-8439
IPO Date
Mar 15, 2013
Website
torii.co.jp
Similar Companies
Whan In Pharm Co.,Ltd. (016580.KS)
Changchun High-Tech Industries (Group) Inc. (000661.SZ)
Univec, Inc. (UNVC)
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (000999.SZ)
HLB Pharmaceutical Co., Ltd (047920.KQ)
Xuanzhubio-b (2575.HK)
Business
Torii Pharmaceutical Co., Ltd. is a Japanese pharmaceutical company engaged in the research, development, manufacture, and marketing of prescription drugs with key focuses on renal diseases, skin diseases, and allergen immunotherapy. Founded in 1872 and headquartered in Tokyo, Japan, the company offers a comprehensive portfolio including therapeutic agents for chronic kidney disease and hemodialysis such as Enaroy tablets for anemia associated with chronic kidney disease, Riona tablets for hyperphosphatemia and iron deficiency anemia, and Remitch for pruritus in dialysis patients. In dermatology, Torii markets topical treatments like CORECTIM, a Janus kinase (JAK) inhibitor ointment, VTAMA cream for atopic dermatitis and plaque psoriasis, and corticosteroid products including Antebate. The company also provides allergen immunotherapy drugs including sublingual tablets for Japanese cedar pollen (CEDARCURE) and mite allergy (MITICURE) and has a long-standing involvement in allergy diagnostics and therapeutics with an extensive product lineup for 29 allergens. As a subsidiary of Japan Tobacco Inc., Torii operates primarily in Japan but extends its reach through strategic alliances, including a collaboration with ALK-Abelló A/S to develop and commercialize allergen immunotherapy drugs. In 2025, Torii entered into an amended collaboration and license agreement with Verrica Pharmaceuticals focusing on the global development of YCANTH, a treatment for common warts, marking a significant strategic expansion into global dermatology markets. Additionally, Torii became a wholly-owned subsidiary of Shionogi & Co., Ltd. following a tender offer completed in 2025, signifying a major restructuring and integration move enhancing its operational and strategic capabilities in the pharmaceutical sector. Torii's business segments include pharmaceuticals for renal disease and hemodialysis; dermatological products targeting inflammatory skin conditions; and allergen products both for diagnosis and treatment of allergies. Its extensive product brands include Enaroy, Riona, Remitch, CORECTIM, VTAMA, Antebate, CEDARCURE, and MITICURE. The company employs over 650 people as of mid-2025 and continues to leverage its century-old expertise in specialty pharmaceuticals for chronic conditions with ongoing R&D and expanded commercialization efforts. Overall, Torii Pharmaceutical stands as a specialized drug manufacturer with focus areas in nephrology, dermatology, and allergology, recently undergoing significant ownership and partnership developments that position it for growth and expanded market presence both domestically and internationally.